Safety of magnetic resonance imaging contrast agents

J Magn Reson Imaging. 1999 Sep;10(3):477-84. doi: 10.1002/(sici)1522-2586(199909)10:3<477::aid-jmri33>3.0.co;2-e.

Abstract

Many of the MR examinations performed in the world each year are accompanied by administration of one of these frequently used intravenous contrast agents: Magnevist, Omniscan, and ProHance. Accordingly, MR practitioners must understand the basic pharmacokinetics, side effects, and the potential for adverse events for these contrast agents. Additionally, MR practitioners must know how to manage side effects and adverse events that may occur in association with the administration of contrast agents. Notably, the use of MR imaging contrast agents in special patient populations must be understood. This article discusses each of these important issues.

Publication types

  • Review

MeSH terms

  • Animals
  • Contrast Media / adverse effects*
  • Contrast Media / pharmacokinetics
  • Contrast Media / toxicity
  • Drug Hypersensitivity / etiology
  • Extravasation of Diagnostic and Therapeutic Materials
  • Gadolinium
  • Gadolinium DTPA / adverse effects
  • Gadolinium DTPA / pharmacokinetics
  • Gadolinium DTPA / toxicity
  • Heterocyclic Compounds / adverse effects
  • Heterocyclic Compounds / pharmacokinetics
  • Heterocyclic Compounds / toxicity
  • Humans
  • Magnetic Resonance Imaging*
  • Organometallic Compounds / adverse effects
  • Organometallic Compounds / pharmacokinetics
  • Organometallic Compounds / toxicity
  • Practice Guidelines as Topic
  • Safety

Substances

  • Contrast Media
  • Heterocyclic Compounds
  • Organometallic Compounds
  • gadoteridol
  • gadodiamide
  • Gadolinium
  • Gadolinium DTPA